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Abstract
Purpose This review summarizes the rationale for the
creationofbreastcentresanddiscussesthestudiesconducted
in Germany to obtain proof of principle for a voluntary,
external benchmarking programme and proof of concept for
third-party dual certiﬁcation of breast centres and their
mandatory quality management systems to the German
Cancer Society (DKG) and German Society of Senology
(DGS) Requirements of Breast Centres and ISO 9001 or
similar. In addition, we report the most recent data on
benchmarkingandcertiﬁcationofbreastcentresinGermany.
Methods Review and summary of pertinent publications.
Literature searches to identify additional relevant studies.
Updates from the DKG/DGS programmes.
Results and conclusions Improvements in surrogate
parameters as represented by structural and process quality
indicators suggest that outcome quality is improving. The
voluntary benchmarking programme has gained wide
acceptance among DKG/DGS-certiﬁed breast centres. This
is evidenced by early results from one of the largest studies
in multidisciplinary cancer services research, initiated by
the DKG and DGS to implement certiﬁed breast centres.
The goal of establishing a nationwide network of certiﬁed
breast centres in Germany can be considered largely
achieved. Nonetheless the network still needs to be
improved, and there is potential for optimization along the
chain of care from mammography screening, interventional
diagnosis and treatment through to follow-up. Specializa-
tion, guideline-concordant procedures as well as certiﬁca-
tion and recertiﬁcation of breast centres remain essential to
achieve further improvements in quality of breast cancer
care and to stabilize and enhance the nationwide provision
of high-quality breast cancer care.
Keywords Guidelines  Certiﬁcation 
Multidisciplinarity  Treatment optimization 
Quality assurance  Benchmarking
Introduction
Breast cancer continues to be the most common malignancy
in women both in Germany and worldwide [1, 2]. In Ger-
many, about 47,500 women were newly diagnosed with
breast cancer in 2000 [3]. More recent estimates put the
ﬁgure at approx. 55,000–58,000 new cases peryear [1,4–6].
Age-standardized incidence of breast cancer remained
essentially constant between 2000 and 2006 but is expected
to rise due to the introduction of mammographic screening
programmes [1]. The average lifetime risk in Germany is
estimatedat9.2–10.9%,meaningthatonaverageonein9–11
women will develop breast cancer during her lifetime [1, 3].
In view of the high incidence of breast cancer and the
recognized fact that the disease requires multidisciplinary
treatment, breast cancer management is prototypical of a
complete process chain of care ranging from early
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longest conceivable process chain of multidisciplinary care
[7]. The diagnosis and treatment of breast cancer involves
numerous interfaces for interaction and collaboration
between medical specialties due to the need for multidis-
ciplinarity and the bisectoral (in-patient vs. out-patient)
nature of healthcare provision, especially in Germany. It
was necessary therefore to centralize breast cancer services
while in parallel creating a breast care network involving
breast centres, breast units and doctors in private practice,
including general practitioners, gynaecologists, medical
oncologist and radiologists. The existing infrastructure in
Germany is optimal and already provides the basis for such
a network. There is a sufﬁcient number of full-service
university hospitals, district hospitals and regular and basic
care hospitals that can collaborate with doctors in private
practice to form a network to provide cancer care of the
highest quality for all patients, whether they are covered by
statutory or private health insurance.
While bisectoral care and multidisciplinary care both
present considerable challenges, they also hold great
potential for optimizing care. As breast cancer is proto-
typical of cancers that require multidisciplinary care, the
disease probably represents the greatest challenge in terms
of care optimization, but on the other hand also opens up
many possibilities for health services research.
Modern oncology, which not only is based on the
multidisciplinary diagnosis and treatment of malignancies
but also is under the obligation to conduct quality assur-
ance, faces the need to both optimize care and create
transparency by introducing quality assurance procedures.
The largest study, to our knowledge, in health services
research and care optimization to date was therefore initi-
ated to investigate these aspects of multidisciplinary
oncology with the aim of evaluating and ultimately
improving the quality of care on the basis of evidence-
based medicine (EBM).
The nature of the problem outlined above made it nec-
essary to iteratively develop a multi-step study design that
would create the preconditions to: (1) deﬁne the interfaces
along the process chain of breast cancer care, (2) stan-
dardize diagnostic and therapeutic procedures in a guide-
line-concordant manner, (3) analyse the importance of a
multidisciplinary approach and (4) generate a body of
EBM data, (5) enable the deﬁnition of standards for the
centralization of breast cancer treatment and (6) review the
quality of care, and (7) use these tools to certify breast
centres.
To achieve these objectives, the following key questions
were addressed:
• What is the rationale for centralizing diagnostic and
therapeutic cancer services?
• Can quality indicators (QIs) be deﬁned and used as key
elements in a benchmarking programme designed to
measure the quality of breast cancer care (‘‘proof of
principle’’)?
• Is it possible to demonstrate that guideline concordance
is achieved by implementation of a quality management
system (QMS) designed to optimize structural, process
and outcome quality; and can a network of quality
assured and hence certiﬁable multidisciplinary breast
centres be created at a national level (‘‘proof of
concept’’)?
To address these questions the German Cancer Society
(DKG) and German Society of Senology (DGS) jointly
initiated the possibly largest multidisciplinary, multicentre
cancer care research project, designed as a prospective
interventional three-phase study (Table 1).
In this review, we discuss the results of this study con-
ducted in Germany and ﬁndings from other pertinent
publications showing that it can now be considered an
established fact that specialized team building and cen-
tralization of breast cancer care in certiﬁed breast cancer
centres result in improved treatment—and, hence,
improved long-term outcome—provided that quality
assurance and QMS are deﬁned and implemented, and the
quality of care is quantitatively evaluated by benchmarking
analysis. In addition, we also present the most recent data
from the relevant programmes for voluntary benchmarking
and certiﬁcation of breast centres in Germany.
Rationale for the creation of breast centres
Since 2003, a large body of data has been collected sys-
tematically from an increasing number of participating
breast centres in Germany. As regards improvements in the
quality of breast cancer care, the following key ﬁndings
have been as follows:
• outcome improves with the number of treated breast
cancer cases (centralization);
• the annual numbers of operations per centre and per
surgeon (specialization) are important, and
• multidisciplinarity is of paramount importance.
These key points, which were open questions until 2003,
have clearly provided the basis for the considerable
improvements in the quality of breast cancer care which
have since been achieved, as will be shown below.
Why the creation of breast centres is important
The speciﬁc question as to the potential signiﬁcant
improvement in patient survival by centralization of breast
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123cancer treatment in hospitals with a certain minimum
annual volume was answered by, inter alia, the landmark
study by Roohan et al. [8]. They analysed the 5-year sur-
vival rate and risk of death for 47,890 breast cancer surgery
patients treated at 266 hospitals in New York State during
1984–1989 in relation to annual hospital volume, deﬁned
as the number of breast cancer surgeries per year. This
analysis demonstrated a signiﬁcant survival advantage for
women treated surgically at centres with more than 150
breast cancer operations per year. Patients treated in hos-
pitals with fewer than ten surgeries/year had a 60%
increase in mortality risk, while the respective mortality
risk for those treated in hospitals with 11–50 and 51–150
surgeries/year dropped to 30% and as little as 19%. More
recently, a retrospective analysis by Guller et al. [9]o f
233,247 patients with unilateral, localized primary breast
cancer treated in the USA during 1988–2000 also found
that high hospital volumes C70 cases/year were associated
with better outcomes for breast-conserving therapy (BCT)
and breast-ablative therapy (BAT). Compared with high-
volume hospitals, low-volume hospitals with B30 cases/
year had a statistically signiﬁcant 3.04-fold increased risk
of death after BCT and a signiﬁcantly increased likelihood
of postoperative complications after both BCT (risk-
adjusted odds ratio (OR) 1.73) and BAT (OR 1.44). Length
of stay was shorter and nonroutine discharge was lower at
high-volume hospitals than at low-volume hospitals.
Especially notable was the ﬁnding that the likelihood of
receiving BCT was signiﬁcantly higher at high-volume
hospitals than at low- and intermediate-volume providers.
Why specialization is important
It has long been established that overall survival increases
with the specialization of the doctors involved in the
diagnosis and treatment of breast cancer. For example, a
study from Scotland investigated 5-year survival in 3,786
female breast cancer patients who underwent surgery
between 1980 and 1988 and were followed up until 1993
[10]. This analysis compared treatment provided by spe-
cialist surgeons with treatment by nonspecialists. Multi-
variate analysis revealed increases by 9 and 8% in the 5-
and 10-year survival rates, respectively, and a reduction in
the risk of death by 16% in patients treated by specialists,
regardless of age, socioeconomic status, tumour size, nodal
status, or grading.
In their milestone publication, Gillis et al. [10] deﬁned
the term ‘‘specialist’’ as a surgeon with a special interest in
the diagnosis and treatment of breast cancer characterized
by the fact that treatment was carried out in a multidisci-
plinary breast centre, in collaboration with specialized
surgeons, pathologists and oncologists there. In addition,
the centre would also organize and conduct collaborative
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123clinical studies and maintain separate records for all
patients with breast cancer in their care.
The role of the specialist surgeon
The connection between specialization and improved out-
come is often attributed to optimized—i.e. guideline-
compliant and individualized—adjuvant therapy, rather
than surgeon experience. However, it is precisely this
signiﬁcant relationship between surgeon annual caseload
and improved 5-year survival rate that was observed by
Sainsbury et al. [11]. They showed that differences in
survival rates existed independently of case mix (age,
tumour stage at primary diagnosis and socioeconomic
status) and could be explained by either surgeon caseload
or treatment regime. Statistical signiﬁcance was observed
for a caseload[30 operations, compared with\10 opera-
tions per surgeon per year. By comparison, the EUSOMA
guidelines [12], for example, recommend an annual case-
load of at least 50 primary operations on newly diagnosed
breast cancers per surgeon. However, Sainsbury et al. [11]
also noted that quality depends crucially not only on
minimum caseload but also on carrying out all treatment in
a multidisciplinary setting.
Furthermore, details of clinical and pathological tumour
stage and hormone receptors are more frequently available
in the case of specialized surgeons [13]. Similarly, Goll-
edge et al. [14] were able to demonstrate improvement in
breast cancer survival rates after the advent of surgical
subspecialization in Bedford, UK, in 1993. On the whole,
before specialization, patients were seen by doctors who
treated 10–38 new cases per year, whereas after the advent
of specialization, diagnosis and treatment were performed
only by doctors who saw 65–75 newly diagnosed breast
cancer patients per year. Comparable tumour-node-metas-
tasis (TNM) stages, patient populations and surgical pro-
cedures (equal percentage of BCT versus mastectomy)
showed respective increases in 1- and 3-year disease-free
survival rates from 87 to 91% and from 70 to 79%.
The improvement in outcome was also associated with a
higher rate of axillary lymphadenectomy and the more
frequent and more appropriate use of systemic chemo-
therapy and hormonal therapy, primarily tamoxifen, which
only became possible with the advent of more accurate
staging by axillary lymphadenectomy. At the same time,
more attention was paid to obtaining a tumour-free surgical
margin, which inter alia had a positive impact in terms of
reducing local recurrence rate. Cady et al. [15] also
emphasized the importance of the surgeon’s correct
assessment of the tumour-free margin, on which the local
recurrence rate depends.
Surgeon specialization and centralization can change not
only the recurrence rate but also the proportion of BCT. A
review by Grilli and co-workers [16] showed that better
surgicalmanagementwas offered,withmoreBCTandmore
appropriate indications for radical surgery/mastectomy. The
rate of mastectomy relative to BCT was higher in smaller
centres,eventhoughtherewerenodifferencesintumoursize
and T1 tumours tended to be more frequent in smaller hos-
pitals than in centres. McKee [17] and Kotwall [18] attrib-
uted this to, inter alia, the lack of multidisciplinary
collaboration with the option of on-site radiation treatment.
The reduction of mortality or increase in 5-year survival
can certainly also be attributed to adjuvant therapy, e.g.
polychemotherapy or tamoxifen, which is more likely to be
offered in a ‘‘high volume’’ hospital [8]. For example, the
well-known meta-analysis of 133 randomized trials pub-
lished by the Early Breast Cancer Trialists Collaborative
Group showed relative improvements in overall survival of
28% for polychemotherapy and 25% for tamoxifen treat-
ment [19].
Other studies reported similar results [10]. They
emphasized that the observed survival beneﬁt associated
with treatment at a specialized centre was primarily the
result of the more frequent and quality-assured adminis-
tration of adjuvant systemic hormonal therapy, chemo-
therapy and radiotherapy, and combinations of these
modalities. For example, although specialists perform
axillary lymphadenectomies better and more frequently, a
better prognosis is not only based on the surgeon’s expe-
rience but also on superior multidisciplinary organization
and relevant experience in the provision of optimal adju-
vant therapy. A more recent study by Kingsmore et al. [20]
investigated the inter-relationship between adequacy of
surgical management, locoregional recurrence and survival
in 2,148 breast cancer patients treated with curative intent.
This study from Scotland found that specialist treatment,
after accounting for case mix and adjuvant therapies, was
associated with a 57% reduction in 8-year local recurrence
rates compared with nonspecialist treatment and that the
risk of death from breast cancer was 20% lower. Kings-
more and colleagues concluded that the adequacy of sur-
gical management was more frequent in specialist breast
units, resulting in lower local and regional recurrence rates
and correspondingly better survival rates.
Why multidisciplinarity is important
All major studies emphasize the fundamental role that
multidisciplinarity plays in improving patient survival. For
instance, the well-known meta-analysis by Richards et al.
[21] found that the 5-year survival rate was better when
patients were treated in a multidisciplinary centre and the
surgeon operated more than 30–50 new cases of breast
cancer per year. Richards and colleagues went even further
in their call for multidisciplinarity in supporting the
1674 Arch Gynecol Obstet (2012) 285:1671–1683
123recommendations of the Calman-Hine report [13]t o
implement a ‘‘hub and spoke’’ model. They showed that a
region such as the West Midlands in the UK with a breast
cancer incidence of 105/100,000 (about 5,250 new cases
per year) required 16 cancer units, each feeding into one of
four breast cancer centres. In this model, the ‘‘hub’’ is a
central academic facility, a university hospital representing
a ‘‘cancer centre’’ that conducts, implements, supervises
and monitors basic research and the introduction of new
treatments and conduct of clinical studies. Richards et al.
considered it crucial to this model to introduce an infor-
mation network to bind the centre and satellite units
together and establish whether these structures lead to
improvements in mortality and quality of life.
It is becoming increasingly clear from the literature, but
only as far as breast cancer is concerned, that multidis-
ciplinarity is more important than surgeon specialization.
The surgical treatment of breast cancer, at least as far as
mastectomy is concerned, is indeed less complex than
surgery for colon or ovarian cancer. Therefore, most cur-
rent discussions hypothesize that in colon and ovarian
cancer it is surgeon caseload that is crucial whereas in
breast cancer it is the caseload (and experience) of the
expert team (radiologist, pathologist, surgeon, medical
oncologist, and radiation oncologist) [22].
The basis of quality assurance
Multidisciplinarycareofpatientswithbreastcancerrequires
a QMS with continuous quality assurance (QA), which
includes comprehensive documentation and external analy-
sisoftheQAdata.Thisisalsoaprerequisiteforbreastcentre
certiﬁcation in accordance with the Requirements of Breast
Centres (Fachliche Anforderungen fu ¨r Brustzentren; FAB)
developed bythe DKG and theDGS.These requirements, in
turn, are based on the two relevant evidence-based, multi-
disciplinary, national level 3 guidelines (S3-LL) for breast
cancer screening in Germany [23] and for the diagnosis and
treatmentofbreastcancerinwomen[24],bothofwhichwere
jointly developed by the DGS, DKG and the relevant sci-
entiﬁc medical societies. Quality of care in breast cancer is
the focus of the joint collaboration between the DGS, the
DKG and the German Society for Gynaecology and
Obstetrics (DGGG) on the one hand and the West German
Breast Centre (WBC), a subsidiary of the German Oncology
Centre (DOC), on the other.
Benchmarking quality of care, certiﬁcation
and nationwide implementation of breast centres
On the initiative of the DKG and DGS a large, nationwide,
multidisciplinary, three-phase multicentre study (see
Table 1) was initiated in 2003 to investigate strategies to
improve the quality of cancer care by introducing voluntary
benchmarking and certiﬁcation programmes and imple-
menting nationwide certiﬁcation of breast centres. The
results of these endeavours are reviewed in the following.
Benchmarking the quality of breast cancer care
Proof of principle
Benchmarking is a continuous process aimed at systemat-
ically improving the quality of care. The benchmarking
concept originates from economics, but can also be applied
to hospitals and the treatments they offer [25]. Generally,
hospitals will differ in terms of performance, showing good
practices in some areas and scope for improvement in
others. Various aspects of performance can be quantiﬁed
by introducing indicators, the highest value for each indi-
cator serving as the benchmark for that speciﬁc aspect of
performance. In the present context, the aspects of per-
formance pertain to the quality of breast cancer care and
are represented by QIs. These can then be used to rank
hospitals to identify the best performer for each QI.
Competing with the best performers may unlock the other
hospitals’ potentials for innovation by identifying ‘‘best
practices’’, modifying these practices appropriately and
adopting them. Thus, each hospital can learn from the
distinctive strengths of other benchmarking partners and
speciﬁcally improve and expand its own service proﬁle. If
conducted anonymously, such benchmarking comparisons
need not be a reason to fear, or risk, loss of prestige [26].
However, any nationwide benchmarking programme
requires the development of an appropriate infrastructure to
collect the necessary data in a standardized manner, cal-
culate QIs according to uniform algorithms and perform a
comparison. Speciﬁc quality objectives can be derived
from operationalized clinical measures and be used as QIs
to assess the quality of a breast centre and to analyse the
changes in quality taking place over a deﬁned observation
period. QIs should represent all three types of quality that
constitute a QMS, i.e. structural quality (e.g. number of
staff and their qualiﬁcations, size of rooms, equipment),
process quality (e.g. co-operation between specialist
departments, communication ﬂow, diagnostic and thera-
peutic parameters), and outcome quality (including com-
plication and recurrence rates, disease-free survival and
patient satisfaction) [26].
In the long term, the indicators of greatest interest in
breast cancer care are those relating to outcome quality, i.e.
morbidity and mortality. However, in breast cancer it often
takes as long as 5–10 years for local recurrences and
metastases to manifest. Breast cancer treatment generally
extends over several years. Therefore it is necessary, at
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123least temporarily, to resort to relevant short- and interme-
diate-term surrogate parameters to assess differences and
improvements in quality over time [27–34]. In effect this
means that during the ﬁrst few years, the benchmarking
programme mainly measures the extent to which the par-
ticipating hospitals implement the guideline recommenda-
tions for diagnosis and treatment.
Little basic research has been done so far to investigate
the impact of centralization and certiﬁcation programmes
in cancer care. To ﬁll this gap, at least with regard to
multidisciplinary breast centres, the ﬁrst-ever prospective
multicentre study investigating the implementation of a
benchmarking programme at breast centres was conducted
in Germany from 2003 to 2007 [35]. The study was
subsequently extended until 2009 [36], and is still ongo-
ing, the data for 2010 recently having become available
[34].
Brucker et al. based their studies on a questionnaire
which comprised 185 individual parameters derived from
the DKG/DGS Requirements of Breast Centres (FAB)
based on the relevant German level-3 guidelines [23, 24].
Specialist breast centres and hospitals with breast care units
in Germany, Austria, Switzerland and the German-speak-
ing parts of northern Italy participated in a benchmarking
project on a voluntary basis. In Germany, a nationwide
collaborative network of multidisciplinary breast centres
was established and an external, independent organization,
WBC, was commissioned by the DKG and DGS to collect
and analyse the relevant data. A purpose-designed XML-
based data set was developed and used for standardized
data collection and calculations using uniform algorithms.
A set of originally nine QIs was derived from guideline-
based quality objectives, reviewed annually and developed
further by modiﬁcation or removal of existing QIs and the
introduction of new QIs. Changes in QIs over time were
analysed descriptively [35].
During the eight-year period from 2003 to 2010, the
number of participating breast centres rose from initially
59 to 210, while the number of primary breast cancers as
conﬁrmed by postoperative histology increased from
5,994 to 34,678 (60% of approximately 58,000 new cases
[1] per year in Germany). By 2010, the initial set of nine
had increased to 18 QIs as surrogate indicators of long-
term outcome quality. The 2003–2010 period saw marked
increases for the following QIs: preoperative histological
conﬁrmation of diagnosis (QI 1; from 58 to 96%);
guideline-concordant endocrine therapy in hormone
receptor-positive patients (QI 6; from 27 to 97%);
guideline-concordant adjuvant and neoadjuvant chemo-
therapy (no age limit) (QI 7.1b; from 32 to 78%);
radiotherapy after breast-conserving surgery (QI 9a; from
20 to 87%); and radiotherapy after mastectomy (QI 10;
from 8 to 74%) [34].
Figure 1 shows the changes in relative performance over
time for all quality indicators for which the DKG/DGS
Requirements of Breast Centres (FAB) speciﬁed perfor-
mance levels for the third year of certiﬁcation. Relative
performance of each quality indicator is expressed as a
percentage of the respective third-year requirement.
The DKG/DGS benchmarking programme thus allows
detailed representation of the entire process chain of breast
cancer care, both with regard to the situation at a particular
moment in time and in terms of changes over time.
Subgroup analysis for a particular specialty
In addition to the overall benchmarking analysis, sub-
groups of relevant QIs can in principle also be used to
demonstrate the extent to which progress has been
achieved, or further improvement may still be needed,
within a given specialty involved in the process. This was
exempliﬁed in a recent analysis of a subset of seven QIs of
direct (QIs 9a, 9b, and 10) or indirect relevance to breast
cancer radiotherapy [36]. The updated results of the subset
analysis are summarized in Table 2, which shows that the
QIs that directly reﬂect the guideline-concordance of
radiotherapy (Nos. 9a, 9b, and 10) increased markedly over
the study period. The percentage of patients given radio-
therapy after breast-conserving surgery (QI 9a) or mas-
tectomy (QI 10) increased from very low levels of 21 and
10% to high levels of 92 and 93%, respectively, relative to
the third-year DKG/DGS minimum requirements of 95 and
80% for certiﬁed breast centres. QI 9b, which was newly
introduced in 2008 to monitor radiotherapy after breast-
conserving surgery (BCS) for ductal carcinoma in situ
(DCIS), increased from 65 to 80%, equivalent to an
increase in relative performance from 68 to 84% of the
DKG/DGS minimum requirement (95% recommendation
for radiotherapy after DCIS treated with BCS). QIs repre-
senting the availability of complete tumour staging data
(No. ex-3), data on safety distance (No. 3), intraoperative
specimen imaging (No. 4) indirectly relate to radiotherapy
in that they reﬂect information that is important to the
multidisciplinary tumour board when deciding on adjuvant
therapy. These QIs also increased, though less markedly,
over the study period.
Overall, the German voluntary programme for the
external benchmarking of the quality of breast cancer care
has produced remarkable results with respect to both breast
cancer care in general and radiotherapy in particular. The
programme has successfully documented the changes in
breast cancer care which have taken place in Germany
since 2003 and, in fact, been a driving force for quality
improvement. The great acceptance of the benchmarking
concept is also evidenced by the increase in case volumes
at the participating DKG/DGS-certiﬁed breast centres in
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been generated describing the reality of breast cancer care
in Germany, and the collection of longitudinal follow-up
data now appears ﬁrmly established.
Certiﬁcation of breast centres: proof of concept
The high incidence of breast cancer and the recognized
need for the provision of appropriate, guideline-concordant
Fig. 1 Relative performance of quality indicators (QIs) during the
2003–2010 period, expressed as a percentage of the respective DKG/
DGS Requirements of Breast Centres (FAB) for the third year of
certiﬁcation (modiﬁed from [36] and updated according to [34]). QIs:
1 = preoperative histological conﬁrmation of diagnosis, 2a = appro-
priate axillary dissection, 2b = patients with sentinel lymph node
biopsy (SLNB), ex-3 = complete tumour staging data, 3 = data on
safety distance between tumour and resection margin, ex-4 = HER
2/neu assessment, 4 = specimen imaging; 5 = hormone receptor
assessment, 6 = guideline-concordant endocrine therapy in hormone
receptor-positive patients, ex-7.1a = guideline-concordant adjuvant
and neoadjuvant chemotherapy during the previous analysis period,
age B70 years, 7.1a = guideline-concordant adjuvant and neoadju-
vant chemotherapy during the current analysis period, age B70 years,
7.2 = adjuvant combination chemotherapy with anthracyclines and/
or taxanes, 8 = percentage of patients in clinical trials, 9a = radio-
therapy after breast-conserving surgery, 9b = radiotherapy after
breast-conserving surgery for ductal carcinoma in situ (DCIS),
10 = radiotherapy after mastectomy, 11b = indication for breast-
conserving therapy at T1
Table 2 Quality indicators (QIs) of direct (9a, 9b, and 10) or indirect ([ex-3] to 8) relevance to radiation oncology and the 2003–2010 changes in
their relative performance compared with the DKG/DGS requirements (modiﬁed and updated from [36] according to [34])
QI no. Quality indicator (QI) Tracked 2003 2004 2005 2006 2007 2008 2009 2010 Third-year
DKG/DGS
requirement
(2010) (%)
[ex-3] Complete tumour staging data 2003–2006 89% 101% 103% 100% ––––[95
3 Data on safety distance between
tumour and resection margin
2007–2010 – – – – 91% 97% 98% 98% 100
4 Specimen radiography
(2007: preoperative in patients with
microcalciﬁcations; 2008: intraoperative)
2007–2010 – – – – 87% 98% 97% 99% [95
8 Percentage of patients in clinical trials 2005–2010 – – 40% 35% 35% 40% 60% 55% C20
9a Radiotherapy after breast-conserving surgery 2003–2010 21% 48% 63% 74% 83% 84% 89% 92% [95
9b Radiotherapy after breast-conserving
surgery for DCIS
2008–2010 – –––– 6 8 % 7 9 % 8 4 % [95
a
10 Radiotherapy after mastectomy 2003–2010 10% 33% 44% 59% 81% 81% 88% 93% [80
a Based on cases of BCS-treated primary DCIS with a recommendation for radiotherapy relative to the total number of cases of BCS-treated
primary DCIS
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123multidisciplinary care make the management of breast
cancer from early detection, diagnosis and treatment
through to follow-up a prototypical example of a complete
multidisciplinary and intersectoral process chain. This
concept formed the starting point for, and was veriﬁed in, a
prospective, iterative, interventional multicentre study
conducted in Germany under the auspices of the DKG and
DGS [22].
The certiﬁcation project began with the ﬁrst pilot cer-
tiﬁcation of a breast centre to ISO 9001 and the DKG/DGS
Requirements of Breast Centres (FAB) in December 2002.
The DKG/DGS dual certiﬁcation procedure in its present
form was established in July 2003. Essentially it combines
compliance with the FAB and the implementation and
maintenance of a certiﬁed QMS at each individual centre.
Proof of concept was demonstrated when the ﬁrst re-
certiﬁcations were achieved. At the end of 2005, the ﬁrst
two DKG/DGS-certiﬁed breast centres successfully
achieved recertiﬁcation after the initial 3-year certiﬁcation.
By mid-2008, 79 out of 80 breast centres had successfully
completed the recertiﬁcation process. One centre failed to
meet the recertiﬁcation requirements in 2007 and was
therefore excluded from further participation in the DKG/
DGS certiﬁcation programme.
During the period from 2004 to 2010, as shown in
Table 3, the number of certiﬁed breast centres increased
from 57 to 200, with the number of single-site centres
increasing from 53 to 149 and the number of two-site
centres increasing from 3 to 46. Since 2006, however, the
proportions of single-site and two-site centres have
remained fairly constant at about 75 and 20–23%, respec-
tively, as has the average number of sites per centre (about
1.3). In contrast, the proportion of multiple-site centres
declined from 6.1 and 4.4% in 2005 and 2006, respectively,
to 2.5% in 2010, indicating a consolidation trend towards
single-site or two-site centres. During 2004–2010, the
number of primary breast cancers treated at a certiﬁed
breast centre increased 4.7-fold from 11,152 to 52,345
cases.
Over the 6-year period from 31 December 2004 until 31
December 2010, the number of new breast cancers per
centre in the ﬁrst year after certiﬁcation increased 1.3-fold
from 196 to 262, while the total number of primary breast
cancers treated at breast centres with dual DKG/DGS
certiﬁcation increased 4.7-fold from 11,152 to 52,345
cases. Thus, in 2010, about 90% of the new cases of breast
cancer in Germany, currently estimated at approx. 57,970
per year [1], were diagnosed and treated at a certiﬁed breast
centre.
Successful nationwide implementation of certiﬁed
breast centres
As recently shown by Wallwiener et al. [37], these updated
results conﬁrm the ﬁndings of the unique descriptive study
by Brucker et al. [22] demonstrating that voluntary certi-
ﬁcation of multidisciplinary breast centres according to the
DKG/DGS dual certiﬁcation procedure is well accepted in
Germany. Moreover, Germany is now close to reaching the
goals set by the European Parliament (EP) to create, by
2008, the conditions required to achieve reductions of 25%
in average breast cancer mortality and of 5% in the dis-
parity in 5-year survival between the countries of the
European Union [38, 39]. Both EP resolutions also called
for the creation of a network of certiﬁed multidisciplinary
breast centres in accordance with the core criteria which
the European Society of Breast Cancer Specialists (EU-
SOMA) published in 2000 and 2004 as Requirements of a
Table 3 Certiﬁcation of breast centres and case volumes at certiﬁed breast centres in Germany during 2004–2010
31 Dec 2004 31 Dec 2005 31 Dec 2006 31 Dec 2007 31 Dec 2008 31 Dec 2009 31 Dec 2010
Certiﬁed breast centres 57 99 135 163 181 195 200
Certiﬁed sites 62 124 176 205 232 250 258
Applications under review 21 24 16 13 10 7 8
Sites per breast centre
1 53 82 102 126 135 146 149
2 3 11 27 34 43 45 46
3 1441123
4 0222222
Primary breast cancers
Total 11,152 20,089 27,722 33,955 41,322 48,289 52,345
Per breast centre 196 203 205 208 228 248 262
Per site 180 162 158 166 178 193 203
Percentage
a 19.2% 34.7% 47.8% 58.6% 71.3% 83.3% 90.3%
a Relative to an estimated 57,970 primary breast cancers in Germany in 2006 [1]
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123specialist breast unit [12, 40], strongly advocating multi-
disciplinarity, specialization and centralization in the pro-
vision of cancer services. In 2005, Brucker et al. [7]
estimated from calculations for the West Midlands in the
UK [21] that in order to meet the EP targets Germany
needed some 250 units and 63 large centres as proposed in
the 1995 Calman-Hine report [13] (Table 4). With 200
breast centres certiﬁed by the end of 2010, Germany is now
well on its way to the reaching the goal of creating a net-
work of specialist breast units and certiﬁed breast centres
according to the ‘‘hub and spoke’’ model of smaller units
feeding into the large centres [21].
Extending the breast centre model to other cancers
Once proof of concept had been demonstrated for the
certiﬁed breast centre, the next important question was to
what extent this ‘‘prototype’’ of a certiﬁed multidisciplin-
ary centre could also be applied to other cancers. Mean-
while, the DKG/DGS certiﬁcation procedure has gained
wide recognition in Germany as a general model for quality
assurance in multidisciplinary cancer care. This has resul-
ted in the creation of other site-speciﬁc and comprehensive
cancer centres. Thus by the end of 2010, there were not
only 200 DKG/DGS-certiﬁed breast centres but also 188
certiﬁed centres for colorectal cancer, 53 for gynaecological
cancers, 63 for prostate cancer, 30 for skin cancer, and
18 for lung cancer in Germany. In addition, 11 compre-
hensive cancer centres had been created for a wide range of
cancers, including pancreatic cancer and head-and-neck
cancers.
Summary and conclusions
Recent developments in German health policies reﬂect the
increasing importance being attached to breast cancer. The
primary aim is to co-ordinate and optimize breast cancer
care in order to reduce the underprovision or overprovision
of care by structured, intersectoral quality management
(QM) [26, 35]. At ﬁrst the shift in health policy thinking
focused on the introduction of disease management pro-
grammes (DMPs) and early detection screening pro-
grammes, including statutory mammographic screening.
The subsequent changes in clinical, scientiﬁc, public health
and socioeconomic thinking necessarily led to a focus on
breast cancer treatment and, consequently, to the called for
improvements in the quality of care [41].
To reduce mortality, improve the quality of life and
increase survival remains the common goal of all parties
involved in the treatment of breast cancer. This requires
quality assurance based on multidisciplinary, specialized
management in a quality-assured, certiﬁed specialist unit
which has a QMS in place and is regularly subjected to
independent audits. The specialist breast units now need to
be further integrated into a comprehensive, supraregional
network within which care is provided according to
(European) guidelines, studies are performed, data are
collected from the network participants and uniformly
documented, network-wide benchmarking is performed on
the basis of uniformly deﬁned QIs. The success of the
implemented quality assurance measures is then assessed
using well-structured documentation based on outcome
quality and the performance of the individual QIs relative
to pre-speciﬁed target values (DKG/DGS Requirements)
[37].
As regards future conceptual orientation, the German
scientiﬁc medical societies will have to continue working
towards promoting quality in oncology both at the national
and the European level. Intensive work in the diagnostic
area, above all, has increasingly enabled women to receive
primary treatment at an early stage, when prognosis is
better. In addition, modern interventional techniques,
especially minimally invasive procedures, to ascertain the
diagnosis have contributed towards reducing delayed
diagnosis and subsequent poorer prognosis. Similarly,
thousands of unnecessary open biopsies can now be
replaced by outpatient diagnostic interventional procedures
every year [42]. The paradigm shift [43]i ntherapeutic
thinking is based on reducing and adjusting the radicality of
surgery to the requirements of the individual patient to
Table 4 Estimated number of
breast units and breast centres
needed in Germany to meet the
European Parliament targets
(from [7]), based on an
extrapolation of the estimate for
the West Midlands region of the
UK [21]
a Based on an incidence of
105/100,000 in a population of
approx. 5,000,000
Country/region Annual new
cases of
breast cancer
Units Centres Units required
by the EP
West Midlands (UK) 5,250
a 16 4 16
Germany 44,274 250 63 250
Baden-Wu ¨rttemberg 5,673 32 8 32
Hesse 3,255 18 4–5 18
North Rhine-Westphalia 9,735 55 14 55
Schleswig–Holstein 1,506 9 2 9
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123preserve the breast whenever possible. This can be
achieved using improved surgical techniques such as
oncoplastic or reconstructive procedures [44], enabling a
growing number of patients to have breast-conserving
surgery while reducing the local recurrence rate due to
histologically complete tumour resection [45].
In addition, systemic tumour control and neoadjuvant
and adjuvant therapy [45] are increasingly being consid-
ered as treatment modalities. Thus, local tumour control
has been integrated into multimodal systemic treatment
strategies based on a deﬁnitive diagnosis by, e.g. diagnostic
sentinel lymph node biopsy [46, 47] or the detection of
disseminated tumour cells [48, 49].
In light of the existing and, in fact, increasingly emo-
tionalized and politicized debate surrounding breast cancer
it has apparently become inevitable to manage QA mea-
sures at the health policy level. Moreover, to improve the
quality of care provided to breast cancer patients, Germany
has recently passed legislation which for the ﬁrst time links
the provision of care to minimum volume requirements.
Under Section 137 of Part Five of the German Social Code
(SGB V), which governs statutory health insurance, the
self-governing bodies within the German statutory health
care system are obliged to determine minimum volumes for
services where quality of outcome depends to a consider-
able degree on the volume of services provided. As of
2004, hospitals failing to meet these minimum volume
requirements have not been authorized to provide such
services. However, deviations from minimum volume
requirements are permissible whenever nationwide provi-
sion of care is at risk.
On the subject of the legally required itemization of
high-quality care, the SGB V stipulates that hospitals
approved under Section 108 as well as prevention and
rehabilitation facilities operating under a Section 111
contract are required to participate in quality assurance
measures which must relate to the quality of treatment,
medical care processes, and treatment outcomes, and must
be designed to allow comparative assessment.
Ultimately it remains unclear, however, to what extent
such nationwide standards of medical stafﬁng, science-
based care, technical equipment, and quality assurance by
QMS implementation are affordable. In this context the
study by Pagano et al. [50] still appears realistic, according
to which the cost analysis for high-quality breast cancer
centres with the appropriate specialization and multidisci-
plinary services indicates that an annual volume of at least
200 primary breast cancers appears favourable from an
economic point of view. An additional factor that makes
nationwide provision of care at this level appear very
doubtful is the cost of permanent availability of multidis-
ciplinary expertise and interaction. Beckmann et al. [51]
analysed the cost-effectiveness of breast centres and
pointed out that substantial portions of the costs of multi-
disciplinarity and centralization, including costs for the
certiﬁcation and re-certiﬁcation, training and continuing
education, research and documentation, did not qualify for
reimbursement under the current reimbursement scheme in
Germany, which is based on the diagnosis-related group
system. They concluded that, under the current reim-
bursement conditions, certiﬁed breast centres could only
exist as an integral part of a hospital where cross-subsidi-
zation from other departments can take place.
As regards the value of creating specialist and com-
prehensive centres and introducing certiﬁcation, the con-
clusion is that despite the positive relationship between
hospital annual case volume and surgeon annual caseload,
and improvement in survival rates, these data do not
necessarily always meet rigorous statistical criteria. It is
clear, however, that multidisciplinarity and quality
assurance are contributing decisively to improving cancer
outcomes. For instance, a very recently published analysis
of the clinical cancer registry data of 3,940 patients from
the German region of Middle Franconia diagnosed with
primary nonmetastatic breast cancer between June 2004
and March 2008 demonstrated that patients treated at
certiﬁed breast centres were younger and had lower dis-
ease stages and lower grading [52]. The authors showed
that, independently of the classical prognostic factors, the
diagnosis and treatment services provided at certiﬁed
breast centres improved the prognosis of breast cancer
patients and attributed this to the quality-assured care
based on the certiﬁcation process. Overall, the introduc-
tion of quality assurance is also raising awareness of the
processes involved in the provision of care and thus
contributing to the improvement of multidisciplinary
collaboration and, consequently, the improvement of
patient care.
In addition to promoting the nationwide provision of
care it is also necessary to promote the implementation of
co-ordinating centres that support and supervise the trans-
fer of the collective data to the benchmarking provider and
the benchmarking analysis itself. These ‘‘centres of
excellence’’ are essential prerequisites, especially with
regard to knowledge transfer, study recruitment, scientiﬁc
analysis and the implementation of current, up-to-date
guidelines. This provides a basis from which the quality
requirements developed by the German scientiﬁc medical
societies can be harmonized with the health policies at the
national and European levels.
Further information and details regarding, for example,
the certiﬁcation bodies, certiﬁcation-related questionnaires
and the DKG/DGS Requirements of Breast Centres are
available online from the German Cancer Society (http://
www.krebsgesellschaft.de) and the German Society of
Senology (http://www.senologie.org).
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123Apart from the necessity to simplify the benchmarking
procedure described above, enable cost-effective central-
ized procedures and reduce the bureaucracy of quality
assurance and certiﬁcation, the German statutory mam-
mography screening programme should remain directly
associated with the certiﬁed breast centres yet also involve
the network of ofﬁce-based specialists. Similarly, in view
of the enormous and, what is more, unreimbursed amount
of time and money spent on documentation, benchmarking
and quality assurance, it is simply inconceivable that var-
ious parallel QA programmes can coexist without being
harmonized. It should be stressed in this context that har-
monization between national and international logical
certiﬁcation procedures has also not yet been implemented.
The fact that breast cancer has a high incidence and
requires multidisciplinary care made this cancer a particu-
larly suitable candidate for assessing whether the instru-
ment of a nationwide quality-of-care benchmarking
programme could serve as a prototype for the creation of
cancer centres in general. In the future, however, the
benchmarking procedure will need to be further standard-
ized, though not only on the basis of the XML data set but
also with regard to the competing programmes in Germany
(DOC vs. BQS/AQUA), which need to be evaluated in a
comparative manner and, if necessary, harmonized.
Finally, the problem should be overcome that at least one-
third of all German breast centres use their own bench-
marking systems.
Practical conclusions
The objective of establishing a Germany-wide network of
certiﬁed multidisciplinary breast centres has largely been
achieved. The next important step, the recertiﬁcation of
previously certiﬁed centres, which demonstrated proof of
concept for the DKG/DGS certiﬁcation programme, is well
on its way and will require the introduction of even higher
standards.
The implementation of certiﬁed multidisciplinary breast
centres in the context of the efforts to optimize the quality of
cancercarecanberightlyconsideredanunparalleledsuccess
storywhichhasalsoreceivedgrowinginternationalattention
[22, 35].Nonetheless,thebreastservicesnetworkstill leaves
scope for improvement along the entire process chain from
mammographic screening, diagnostic interventions and
treatment at a breast centre through to long-term follow-up.
At the present stage the true endpoints of breast cancer
treatment, which include the long-term survival rate and
the rates of recurrence and metastasis as indicators of
outcome quality, can only be approximated by indicators of
structural and process quality as surrogate endpoints. Even
so, certiﬁed and uncertiﬁed breast centres tend to differ in
respect of guideline-concordant treatment, also referred to
as guideline compliance. Nevertheless, these differences
can be expected to decrease as public awareness of these
issues grows and the desirable turn to EBM as represented
by the level-3 guidelines progresses. Thus it increasingly
appears that developments in the quality of breast cancer
care are reﬂecting the dictum that ‘‘the journey is the
destination’’.
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